edotreotide has been researched along with Carcinoma, Neuroendocrine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G | 1 |
| Cornelissen, C; Frechen, D; Krüger, S; Kweider, S; Temur, Y | 1 |
| Bertagna, F; Bettinsoli, G; Biasiotto, G; Bosio, G; Dognini, L; Ferrari, C; Ferrari, V; Franco, F; Giubbini, R; Migliorati, E; Minari, C; Rodella, C; Savelli, G; Tomassetti, P; Zaniboni, A | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Karwal, M; Madsen, M; Menda, Y; O'Dorisio, T; Parker, S; Ponto, J; Ponto, L; Zehr, P | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
| Brunner, FP; Maecke, HR; Mihatsch, MJ; Moll, S; Mueller-Brand, J; Nickeleit, V | 1 |
3 trial(s) available for edotreotide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Retreatment; Survival Rate; Yttrium Radioisotopes | 2012 |
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
Topics: Alanine Transaminase; Alkaline Phosphatase; Analysis of Variance; Aspartate Aminotransferases; Carcinoma, Neuroendocrine; Clinical Protocols; Disease Progression; Humans; Liver; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2003 |
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
3 other study(ies) available for edotreotide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome | 2016 |
[Neuroendocrine pulmonary neoplasms: improved diagnosis by DOTATOC- vs. FDG-PET/CT].
Topics: Biopsy; Bone Neoplasms; Carcinoma, Neuroendocrine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lumbar Vertebrae; Lung; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Octreotide; Positron-Emission Tomography; Ribs; Sacrum; Spinal Neoplasms; Tomography, X-Ray Computed | 2011 |
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
Topics: Biopsy; Carcinoma, Neuroendocrine; Female; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Octreotide; Radiation Injuries; Thrombosis; Yttrium Radioisotopes | 2001 |